Canadian Journal of Infectious Diseases and Medical Microbiology

Canadian Journal of Infectious Diseases and Medical Microbiology / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 5763595 |

Mohan Rao, Fairuz Amran, Nadia Aqilla, "Evaluation of a Rapid Kit for Detection of IgM against Leptospira in Human", Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 2019, Article ID 5763595, 4 pages, 2019.

Evaluation of a Rapid Kit for Detection of IgM against Leptospira in Human

Academic Editor: Maria Lina Tornesello
Received19 Oct 2018
Revised09 Jan 2019
Accepted23 Jan 2019
Published07 Feb 2019


Introduction. Leptospirosis is an acute febrile illness, known for its protean clinical manifestations and the challenge in differentiating from other infectious diseases. Standardized confirmatory test is antibody dependent and not accessible by the suburban community. This study measures efficiency of an immune-chromatographic assay, Leptocheck WB, in detecting acute leptospirosis. Methods. A total of 142 sera were used for kit evaluation. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated by comparing rapid kit results with gold standard laboratory, microscopic agglutination test (MAT). Results. We found this rapid kit to have a sensitivity and specificity of 66.6% and 78.9%, respectively, whereas the PPV and NPV of the kit appeared to be 73.3% and 73.2%, respectively. Discussion. Test efficiency of this rapid kit is reasonable. It is specific in detecting leptospiral antibody and assures clinician of accurate diagnosis by having higher PPV and NPV. It is prompt and efficient in comparison with conventional methods in assisting differential diagnosis. High sensitivity and specificity leptospirosis rapid test is indeed a crucial measure to assist the diagnosis of acute undifferentiated febrile illnesses.

1. Introduction

Acute febrile illness is a clinical syndrome, contributes to substantial morbidity and mortality worldwide [1]. The epidemiology of infectious cause varies from one country to another country [2, 3]. Leptospirosis is underrecognized but the common cause of acute febrile illness [4]. Its global distribution ranging from 10 to 100 human cases per 100000 individuals with higher incidence is commonly found in tropics and subtropics [5].

Leptospirosis is caused by pathogenic species of the spirochete Leptospira. It is known for its protean manifestations, from being asymptomatic to a severe disease with multiple organ failure that requires intensive care approach [6]. High fever, headache, chills, arthralgia, myalgia, jaundice, diarrhea, nausea, and vomiting are common symptoms manifested by the illness [7]. Often times, it is difficult to differentiate, due to its nonspecific clinical manifestations and poor background knowledge on infectious epidemiology [8, 9]. Failure to recognize leptospirosis delays antibiotic administration and may lead to poor outcomes [10].

Confirmatory laboratory test is very crucial for optimal treatment and management of the illness. Microscopic agglutination test (MAT), organism DNA detection via nucleic acid amplification test (NAAT), enzyme-linked immunosorbent assay (ELISA), and organism isolation via culture method are a few tests performed in our reference laboratory. However, there are limitations to their use and interpretation of the results. These tests are tedious, sophisticated, time-consuming, and operator dependent; therefore, they are not suited for early diagnosis [11]. Hence, a timely manner diagnosis in conjunction with laboratory support such as rapid test is often preferred in the hospital environment. Any efforts in developing a novel diagnostic kit for rapid diagnosis of leptospirosis are appreciable, valuable, and significant. Early diagnosis is possible by having an ideal laboratory support that is rapid, sensitive, safe, simple, and economical [12].

Leptocheck WB is a bedside, rapid, and qualitative diagnostic kit used for preliminary diagnosis of leptospirosis. It utilizes the principle of agglutination of antibodies with respective antigen in immunochromatography format along with the use of nanogold particles as agglutination revealing agent. As the serum flows through the membrane assembly of the kit, agglutinating sera for human IgM-colloidal gold conjugate forms complexes with IgM antibodies in the sample. As these complexes move further on the membrane, they will be immobilized by Leptospira genus specific antigens coated on the membrane, leading to the formation of red- to purple- coloured band at the region “T” of the kit indicating presence of Leptospira IgM antibodies.

We have evaluated a solid-phase commercial gold immunochromatographic assay kit (ICA), which was manufactured by Zephyr Biomedicals, Goa, India. This kit was evaluated for its efficacy identifying Leptospira antibodies in acute sera, plasma, or blood for rapid bedside screening.

2. Materials and Methods

This diagnostic kit evaluation was conducted in Reference Laboratory for Leptospirosis, Institute for Medical Research (IMR), Kuala Lumpur. It was performed by trained laboratory technician.

2.1. Microscopic Agglutination Test

The current gold standard for the laboratory diagnosis of leptospirosis is the microscopic agglutination test (MAT). MAT was performed on all the sera using a panel of 20 serovars recommended by the WHO Collaborative Centre for Leptospirosis and 6 local isolates. The reference strains obtained from the WHO Collaborative Centre for Leptospirosis, Amsterdam are Australis, Autumnalis, Bataviae, Ballum, Canicola, Grippotyphosa, Icterohaemorrhagiae, Javanica, Pomona, Pyrogenes, Tarrasovi, Sejroe, and Patoc [5, 13].

2.2. Sera/Plasma Selection

A total of 142 sera were used in this evaluation. Among these sera, 66 were positive and 76 were negative. Thirty-one paired samples (62 sera) were gathered to test the efficiency in detecting IgM of Leptospira; however, these sera were not included in the diagnostic performance calculation. Sera were considered positive if the MAT titer was ≥400 or with 4-fold rise in titer detected between acute (≤7 days of illness) and convalescent sera (≥7 days of illness) from the same patient. Meanwhile, sera were considered negative if MAT titer is ≤ 50, indicating other infective causes [14]. These are retrospective sera of patients recruited from various hospitals localized in Federal Territory, Selangor and Pahang State, Malaysia. They were sera sent to IMR for laboratory diagnosis of leptospirosis.

An additional 50 sera, tested positive for other infectious diseases, were obtained from the serology laboratory in Institute for Medical Research. Ten positive sera, respectively, from melioidosis, Brucellosis, Rickettsioses, dengue NS1 positive, and dengue IgM were used to assess the cross-reactivity status of the ICA. These sera were not included in the study of diagnostic performance.

2.3. Procedure of Test

Leptocheck WB, Zephyr Biomedical, India, is a rapid test kit evaluated in this study. According to the manufacturer, this kit is designed for the detection of the acute-phase antibody, IgM. The principle of the test is based on the immunochromatographic agglutination of circulating antibodies with specific antigen using nanogold particles as the agglutination revealing agent. Samples in the form of sera, plasma, or blood were tested on the evaluation kit as per instruction by the manufacturer. Result interpretation is solely based on the appearance of the red band within designated time. Figure 1 explains the subjective visual interpretation of the test kit.

2.4. Data Analysis

Diagnostic performance was calculated by comparing ICA results with MAT of selected sera by tabulating the results in a crosstab formula. True positive, true negative, false positive, and false negative results were identified. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the diagnostic kit were calculated using the following formulas:

3. Results

In this study, 44 of 66 positive leptospirosis cases were tested positive using the ICA giving a case sensitivity of 66.6%. Sixty of 76 negative leptospirosis cases were tested negative for ICA, resulting in a specificity of 78.9%. The positive predictive value (PPV) and the negative predictive value (NPV) of the assay were 73.3% and 73.2%, respectively. Results are as tabulated in Tables 1 and 2. In terms of cross-reactivity evaluation, minimal cross activities were observed with dengue and melioidosis sera at a percentage of 10% and 20%, respectively (Table 3), whereas 14/31 (45%) acute sera among the paired samples were positive using ICA; albeit MAT titer were either negative or inconclusive.

Microscopic agglutination test (MAT)

ICA Leptocheck WB Leptospira rapid test kitPositive44 (true positive)16 (false positive)60
Negative22 (false negative)60 (true negative)82

Statistical measurementTest efficiencies (%)


Serum samples tested positive serologically to other infectious diseasesLeptocheck WB rapid test for IgM antibodies to LeptospiraPercentage of cross-reactivity between immunochromatographic tests with other infectious diseases (%)

Dengue (IgM positive)1910
Dengue (NS1 positive)1910

4. Discussion

Diagnosis of acute febrile illness is difficult in tropical settings where many possible etiologies can be responsible for the illness. The urgency for rapid diagnosis of leptospirosis is necessary for accurate antibacterial therapy and to evade impending complications [6]. Commonly, leptospirosis remained underrecognized or misdiagnosed due to their paradoxical clinical manifestations. Molecular-based methods involving real-time PCR have been successful in providing rapid diagnosis [15]; however, its requirements for specialized personnel, sophisticated equipment, and expensive rather made it harder for urgent diagnosis.

In our evaluation, the test efficiency of this immunochromatographic assay was generally lower than those reported previously [16, 17, 18]. This rapid kit was found to be moderately sensitive and specific with acceptable PPV. Its performance was particularly moderate for samples collected within first week of illness. Unfortunately, this time interval is crucial for therapeutic decision.

Although the sensitivity of the kit is lower than the specificity, this could be reasoned by no available or inadequate antibody in the acute sera/early phase of infection [19]. It is beyond the capability of the kit in detecting low-level antibody. Therefore, it is advisable to repeat the test after the period of seroconversion. On the contrary, the antigen used in this agglutination principled test plays a major role in estimating the efficiency of the test. Negative test on serial samples does not rule out the probability of the infection since the choice of “antigen coverage” coated in the kit (not disclosed by the manufacturer due to confidentiality) is probably not within our local spectrum, resulting in false negative outcome [20].

In this study, we discovered that the kit has reasonable PPV and NPV. These findings allow clinicians to narrow down the diagnosis as this kit is specific in detecting Leptospira IgM antibody. Therefore, it encourages initiation of appropriate therapy without a delay [10]. As the specificity of this test kit is moderate, it permits minimal cross-reactivity with other acute febrile illnesses. Hence, it is particularly difficult to determine the actual diagnosis and can be only confirmed via culture or polymerase chain reaction to detect the DNA of the respective bacteria or virus. However, this approach is deemed not possible as many peripheral laboratories are not equipped to do so.

Other than providing reasonable results, this test kit has several other advantages. In comparison with tedious and time-consuming gold standard MAT and ELISA test [11], this test kit is rapid in providing result within given time scale, simple to perform, without the need of sophisticated equipment. It can be performed at bedsides, in the laboratories, or at the field. The test can be used in resource-poor settings, by investigators with only limited training [12]. However, MAT and ELISA remained as the gold standard laboratory diagnosis despite being tedious and sophisticated due to their vast antigen coverage from different serogroups and serotypes, serial dilution of sera to appreciate seroconversion and to overcome the prozone effect.

In view of multiple cause of acute febrile illness, patients’ medical history and clinical assessment are not sufficient in providing absolute diagnosis. Screening test that is sensitive and specific in the acute phase of infection would be of great benefit for health care. In reemerging zoonosis, a rapid diagnosis of leptospirosis would help physicians in providing appropriate treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors of this study have no work in relation to the company of Leptocheck WB, Zephyr Biomedical, India, or its products. The authors have no potential conflicts of interest to disclose.


This study was funded by the Diagnostic Operational Budget from the Leptospirosis Reference Laboratory of Bacteriology Unit, Institute for Medical Research, Ministry of Health Malaysia, 50588 Jalan Pahang, Kuala Lumpur. The authors would like to thank the Director General of Ministry of Health Malaysia for allowing us to publish our findings.


  1. L. Liu, H. L. Johnson, S. Cousens et al., “Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000,” The Lancet, vol. 379, no. 9832, pp. 2151–2161, 2012. View at: Publisher Site | Google Scholar
  2. S. Afifi, F. Mahoney, H. Mansour et al., “Hospital-based surveillance for acute febrile illness in Egypt: a focus on community-acquired bloodstream infections,” The American Journal of Tropical Medicine and Hygiene, vol. 73, no. 2, pp. 392–399, 2005. View at: Publisher Site | Google Scholar
  3. D. R. Murdoch, C. W. Woods, M. D. Zimmerman et al., “The etiology of febrile illness in adults presenting to Patan Hospital In Kathmandu, Nepal,” The American Journal of Tropical Medicine and Hygiene, vol. 70, no. 6, pp. 670–675, 2004. View at: Google Scholar
  4. M. E. Reller, E. A. Wunder, J. J. Miles et al., “Unsuspected leptospirosis is a cause of acute febrile illness in Nicaragua,” PLoS Neglected Tropical Diseases, vol. 8, no. 7, p. e2941, 2014. View at: Publisher Site | Google Scholar
  5. World Health Organization (WHO) and International Leptospirosis Society (ILS), Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control. WHO Library Cataloguing-in-Publication Data, World Health Organization (WHO) and International Leptospirosis Society (ILS), Vancouver, Canada, 2003,
  6. P. N. Levett, “Leptospirosis,” Clinical Microbiology, vol. 14, no. 2, pp. 296–326, 2001. View at: Publisher Site | Google Scholar
  7. Signs and Symptoms | Leptospirosis | CDC, 2019,
  8. V. A. Murugaiyah, S. Lecturer, J. K. Lim et al., “A case study: leptospirosis in Malaysia,” 2011, View at: Google Scholar
  9. C. Suttinont, K. Losuwanaluk, K. Niwatayakul et al., “Causes of acute, undifferentiated, febrile illness in rural Thailand: results of a prospective observational study,” Annals of Tropical Medicine and Parasitology, vol. 100, no. 4, pp. 363–370, 2006. View at: Publisher Site | Google Scholar
  10. E. L. Gouveia, J. Metcalfe, A. Luiza et al., “Leptospirosis-associated Severe Pulmonary Hemorrhagic Syndrome, Salvador, Brazil,” Emerging Infectious Diseases, vol. 14, no. 3, pp. 505–508, 2008. View at: Publisher Site | Google Scholar
  11. M. A. Guerra, “Leptospirosis: public health perspectives,” Biologicals, vol. 41, pp. 295–297, 2013. View at: Publisher Site | Google Scholar
  12. World Health Organization (WHO), WHO | Urgently Needed: Rapid, Sensitive, Safe and Simple Diagnostic Tests, WHO, Geneva, Switzerland, 2015.
  13. Zoonosis Division-National Institute of Communicable Diseases, Guidelines for Prevention and Control of Leptospirosis, Zoonosis Division-National Institute of Communicable Diseases, Delhi, India, 2006.
  14. Cibulskis, “Guidelines for the diagnosis, management, prevention and control of leptospirosis in Malaysia,” 2011, View at: Google Scholar
  15. P. Saisongkorh, S. C. Sehgal, M. G. A. Goris, W. J. Terpstra, and R. A. Hartskeerl, “Leptospira interrogans serovar Valbuzzi: a cause of severe pulmonary haemorrhages in the Andaman Islands,” Journal of Medical Microbiology, vol. 52, no. 10, pp. 913–918, 2003. View at: Publisher Site | Google Scholar
  16. G. Doungchawee, D. Sutdan, K. Niwatayakul et al., “Development and evaluation of an immunochromatographic assay to detect serum anti-leptospiral lipopolysaccharide IgM in acute leptospirosis,” Scientific Reports, vol. 7, no. 1, p. 2309, 2017. View at: Publisher Site | Google Scholar
  17. N. Journal, C. Medicine, and T. Panwala, Seroprevalece of Leptospirosis in South Gujarat Region by Evaluating the Two Rapid Commercial Diagnostic ..., (January 2011), 2015.
  18. L. J. Dumler, S. Mulla, M. G. Patel, and G. Vaghela, “Outbreak surveillance report on pulmonary leptospirosis after a heavy floods during 2006 in south Gujarat,” National Journal of Medical Research, vol. 2, 2012. View at: Google Scholar
  19. D. A. Haake and P. N. Levett, “Leptospirosis in humans,” in Current Topics in Microbiology and Immunology, vol. 387, Springer, Berlin, Heidelberg, 2015. View at: Publisher Site | Google Scholar
  20. H. Korver Department of Biomedical Research and Institute, “Microscopic agglutination test (Mat) for the diagnosis of leptospirosis and serotyping of leptospires,” 2019, View at: Google Scholar

Copyright © 2019 Mohan Rao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

4077 Views | 694 Downloads | 0 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.